
innovation
Support for innovative projects: 2025 results of the internal "DARRI/Carnot" call for proposals
Each year, an open call funded by the Technology Transfer and Industrial Partnerships Department (DARRI) and the institut Carnot Pasteur Microbes & Santé (the Institut Pasteur has been part of the Carnot network since the accreditation was first introduced) provides support for innovation development programs, offering a maximum grant of €150,000 over 12-24 months for each selected program.
The projects submitted are analyzed by an ad hoc committee composed of scientists from Pasteur, members of the Consultative Innovation Committee, members of DARRI, Scientific Affairs Division and insdustrial world.
Projects at an early stage may apply for the EMERGENCE call. The aim at the end of these projects is to create intellectual property.
Projects at an advanced stage may apply for the MATURATION call. The technology readiness level (TRL) expected for this type of project is higher than for EMERGENCE projects. The aim is to strengthen an existing proof of concept.
The 2025 winners of the DARRI/Pasteur Microbes and Health Carnot Institute call for proposals are:
Pedro Escoll Guerrero (Biology of Intracellular Bacteria Unit): Real-Time Monitoring of Mitochondrial Signatures in PBMCs: An AI-Driven Approach for Sepsis Prognosis and Therapy Guidance
Sean Kennedy (InBio Unit - Experimental and Computational Methods for Modeling Cellular Processes): Forensic-Dx: development of forensic "diagnostics" based on microbiome
Pierre Buffet (Spleen, Parasites & Infections Laboratory): RAMP-iT (Ravidasvir Against Malaria Parasites in Travelers)
Emilie Giraud (Chemogenomic and Biological Screening Platform): Development of broad-spectrum antisense oligonucleotides therapeutics targeting Orthoflavivirus
Brendan Evano (Stem Cells and Development Unit): Targeted Genetic Manipulation of Muscle Stem Cells in vivo: Towards New Treatment Strategies Against Muscular Dystrophies
Ignaco Fernandez (Structural Virology Unit): Design of stable and highly expressed antigens for a preclinical HTLV-1 vaccine.